Acerus Pharmaceuticals has announced that the agreement with Endo International relating to the commercialization of NATESTO™ in the United States and Mexico will be terminated, effective June 30, 2016.
Under the terms of the agreement with Acerus, Endo will continue to sell and distribute NATESTO™ in the U.S. until the effective date of termination.
“While we are disappointed with Endo’s previously announced strategic business decision to realign their U.S. branded resources from urology retail to their pain franchise, we are fully committed to the continued success of NATESTO™ in the U.S.,” said Tom Rossi, President and Chief Executive Officer of Acerus. “Our immediate focus is on finding a new NATESTO™ partner in the U.S., the largest market for testosterone replacement therapy. We are encouraged by the positive physician and patient feedback received on the product to date, and believe there will be strong interest from other companies to step in and continue to drive the launch of NATESTO™.”